Search

Search Constraints

You searched for: Author/Creator Shah, Jatin

Search Results

1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

4. A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Issue 13 (10th November 2021)

5. A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. Issue 2 (30th November 2021)

6. A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. (March 2022)

7. A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events. (19th August 2014)

8. Assessing the quality of life of head and neck healthcare workers during the COVID‐19 pandemic—A self‐reported global cross‐sectional questionnaire study by the International Federation of Head and Neck Oncologic Societies. Issue 4 (9th June 2021)

9. Cervical Lymph Node Metastasis in Adenoid Cystic Carcinoma of the Larynx: A Collective International Review. Issue 4 (April 2016)

10. Cervical Lymph Node Metastasis in High-Grade Transformation of Head and Neck Adenoid Cystic Carcinoma: A Collective International Review. Issue 3 (March 2016)